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Background/aim: This study investigated the effect of vascular endothelial growth factor (VEGF) inhibitor bevacuzimab (BVZ) on the
rabbit basilar artery using an experimental subarachnoid hemorrhage (SAH) model.
Materials and methods: Eighteen adult male New-Zealand white rabbits were randomly divided into three groups: a control group (n
= 6), SAH group (n = 6), and SAH+BVZ group (n = 6). Experimental SAH was created by injecting autologous arterial blood into the
cisterna magna. In the treatment group, the subjects were administered a daily dose of 10 mg/kg, intravenous BVZ for 2 days after the
SAH. Basilar artery diameters were measured with magnetic resonance angiography (MRA) 72 h after the SAH in all groups. After 72
h, whole brains, including the upper cervical region, were obtained from all the animals after perfusion and fixation of the animal. The
wall thickness, luminal area, and the apoptosis at the basilar arteries were evaluated in all groups.
Results: BVZ significantly prevented SAH-induced vasospasm confirmed in vivo with MRA imaging with additional suppression of
apoptosis on basilar artery wall.
Conclusion: VEGF inhibition with BVZ has shown to have a vasospasm and apoptosis attenuating effect on basilar artery in a SAH
model.
Key words: Apoptosis, bevacizumab, subarachnoid hemorrhage, vasoconstriction, vascular endothelial growth factors

1. Introduction
Cerebral vasospasm is one of the most important causes
of mortality and morbidity in subarachnoid hemorrhage.
Vasospasm seems to be a multifactorial and complicated
process without any clear etiology or effective treatment
[1,2]. The endoplasmic reticulum stress-mediated apoptosis
pathway is considered to play a vital role in mediating
stroke and other cerebrovascular diseases like subarachnoid
hemorrhage (SAH) [3].
In clinical settings and experimental SAH models, vascular
endothelial growth factors (VEGF) were reported to increase
in acute phase of aneurysmal SAH, and were suggested to
cause cerebral vasospasm and proliferative angiopathy [4–6].
Therefore, we hypothesized that anti-VEGF therapy may
have a restorative effect after SAH. Bevacizumab (BVZ) is

a humanized monoclonal antibody with a long half-life (22
days) that inhibits the VEGF. It has been used to treat certain
malignancies including breast, lung, renal, and colorectal
carcinomas [7]. Available data on the relationship between
anti-VEGF therapy and SAH is limited and not well described.
VEGF has been shown to stimulate the production of nitric
oxide by endothelial cells in arteries and arterioles, resulting
in vasodilation [8]. Thus, there is a concern for anti-VEGF
therapies causing angiogenic blockage increasing the risk of
vasospasm [9,10]. Indeed, retinal arterial vasoconstriction and
systemic hypertension have been identified as complications
of anti-VEGF therapy [11].
Our study aimed to investigate the effect of VEGF
antagonism on cerebral vasospasm and related apoptotic cell
death after experimental SAH injury.
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2. Materials and methods
This study was done under the control of animal
experiments local ethic committee at Ankara Training
and Research Hospital, Animal Experiments Research
Laboratory, Ankara, Turkey between 09/10/2013 and
14/10/2013 (Decision number: 232). The animals
underwent the magnetic resonance angiography (MRA)
investigations at Dışkapı Y.B. Training and Research
Hospital, Ankara, Turkey. The microscopic basilar
artery diameter measurements and histopathologic
investigations were performed at the Ankara University
Medical Faculty’s Histology–Embryology Department,
Ankara, Turkey (D.B, S.A).
A total of 18 New-Zealand white rabbits (weight range:
2.5–3.0 kg) were used in this study. All subjects were kept
under stable and standard environmental conditions
during the experiment and received standard animal feed
as well as free access to water during the experiment.
2.1. Groups
Three groups of animals were created, each of which
consisted of six animals. Control group (Group 1): Animals
were given general anesthesia without any surgical
intervention. SAH group (Group 2): SAH was created
and the group underwent intravascular administration of
saline for a total of 3 days starting 2 h after the creation of
SAH. Treatment group (Group 3, SAH+BVZ group): 120
min after SAH, 10 mg/kg BVZ (Avastin(R), Genentech,
Inc. South San Francisco, CA, USA) was given through
intravascular injection. Additional two doses were given
24 and 48 h after SAH.
2.2. SAH model
The rabbits were administered 50 mg/kg ketamine
hydrochloride and 10 mg/kg xylazine (Alfazyne(R) 2%
vial, Ege-Vet, Turkey) intramuscular doses before the
surgical procedure. General anesthesia was ensured, and
the rabbits were left to their spontaneous respiration. No
ventilator support was used during the experiment.
In the subarachnoid hemorrhage model, the occiput
and posterior neck of the rabbits were shaved according
to aseptic rules. Cerebrospinal fluid (1 mL) was drained
from subarachnoid space via cisternal puncture. Auricular
arteries of animals in groups 2 and 3 were cannulated
via 24-gauge catheter while 2 mlL of blood was drained.
Drained blood was slowly injected (after 2 min) to cisterna
magna of rabbits in group 2 and group 3. After the blood
injection, rabbits were positioned downward for 15 min
for the distribution of blood to basal cisterns.
Animals were observed at 23–25 °C. On the 3rd day of
the experiment, after performing MRA, the animals were
given general anesthesia. Under anesthesia, abdominal and
thoracic cavities of the animals were opened. Descending
aorta was clamped and the heart was cannulated to aorta
via ventricular puncture. Perfusion of the animals was

performed via 0.9% NaCl, followed by 4% formaldehyde.
The entire brains, including the upper cervical regions,
were kept in 10% formaldehyde at 4 °C.
2.3. MR angiography
All subjects were administered 10 mg/kg ketamine
hydrochloride
(Ketalar
vial(R),
Pfizer,
USA)
intramuscularly for sedation on the third day of the
study. They then underwent cerebral 1.5-T MRA (Philips
Healthcare, Eindhoven, the Netherlands). All MRA images
were recorded and measured digitally. Measurements
were performed to pass through each basilar artery in five
separate segments in the vertical plane, the images were
then evaluated statistically.
2.4. Histological study
2.4.1. Tissue preparation
The brain and brainstem were removed and fixed in 10%
buffered formalin. For assessment of vasospasm, the entire
basilar artery of each animal was collected and sectioned
at 5 segments, each being 2 mm in length. The basilar
artery samples were dehydrated in a graded ethanol series,
cleared in xylene, and embedded in paraffin. Sections were
cut to 5-μm thicknesses using a microtome (Leica RM
2125RT, Leica, Wetzlar, Germany) and were stained with
hematoxylin and eosin (H-E). Slides were examined and
photographed using Axio Scope-A1 (Carl Zeiss, Germany)
microscope at 100× magnification.
2.4.2. Histomorphometric analysis of the basilar artery
The wall thickness and luminal area of the predetermined
five segments of basilar arteries were measured using
Axiovision software program (AxioVision, Oberkochen,
Germany). The wall thickness was measured at four
quadrants of each segment of the basilar artery between
endothelium of intima and external border of tunica
media. Luminal area was calculated from luminal borders
of each segment. The results were recorded and evaluated
statistically.
2.4.3. Assessment of apoptotic cells
Under light microscopic examination, the apoptotic cell
percentage was calculated by comparing TUNEL-positive
stained cells with the complete cell count, including the
entire circumferential vessel wall. The examination was
done by histologists who were blinded to the study.
For TUNEL staining, immunohistochemical detection
of cells undergoing DNA fragmentation was performed
using a terminal deoxynucleotidyl transferase (TdT)
labeling (TUNEL) method with a commercial in situ
apoptosis detection kit (ApopTag Peroxidase in Situ
Apoptosis Detection Kit, Millipore, Darmstadt, Germany,
S7100). The 5-μm-thick sections were stained according
to the manufacturer’s protocol for the Peroxidase in Situ
Apoptosis Detection Kit. Diaminobenzidine (DAB) was
used as a chromogen, and counterstaining was performed
using methyl green.
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2.5. Statistical analysis
We used means with standard error for continuous
variables, respectively plus or minus standard error. A
normality test was done prior to analysis. If the normality
test revealed that data were normally distributed, statistical
differences between the groups were compared by oneway analysis of variance (ANOVA). Then post-Tukey
multiple comparison tests were performed if a significant
difference had been determined. If the normality test
revealed that the data were not normally distributed, the
Kruskal–Wallis test was performed. Post hoc analysis was
performed between the groups if the data was statistically
significant. A probability (p) value of <0.05 was considered
statistically significant. Statistical analysis was performed
using Prism 9 for Mac (Graphpad Prism, CA, US).
3. Results
All animals survived the 3 days after SAH, and MRA and
histopathological assessments were performed for each of
the animals.
3.1. MR angiography
The mean artery diameters of the basilar arteries of the
MRA was different for the three groups (p < 0.0001,
the Kruskal–Wallis test). The mean MRA basilar artery
diameter was found to be 0.104 ± 0.003 mm in the control
group, 0.071 ± 0.011 mm in the SAH group, and 0.089 ±
0.003 mm in the SAH+BVZ group. In the control group,
the mean basilar artery diameter was found to be higher
than the SAH group (p < 0.001). The mean diameter of

the artery was higher in the SAH+BVZ group compared
to SAH group (p < 0.05) (Figure 1, Table).
3.2. Histologic assessment
After removing the brain and the brainstem, widespread
SAH was observed macroscopically in the ventral
surface of the brain in all SAH and SAH+BVZ groups. A
histomorphology assessment was performed on samples
with H-E and TUNEL staining. According to H-E staining
of the control group, three layers of the basilar artery
wall, tunica intima, tunica media, and tunica adventitia,
were observed at normal appearance (Figure 2Aa). In the
SAH group, narrowed basilar artery lumen, shrunken
endothelial cells, corrugated internal elastic membrane,
thickened vessel wall, and contracted smooth muscle
cells were seen (Figure 2Ab). In the SAH+BVZ group,
the basilar artery lumen was larger and the vessel wall
was thinner than the SAH group. The internal elastic
membrane was smooth, endothelial cells were normally
shaped, and smooth muscle cells were elongated (Figure
2Ac).
3.3. Analysis of intergroup wall thickness and luminal
area
Evaluation of the basilar artery luminal area showed
a significant difference between the three groups (p <
0.05, ANOVA). The mean vessel lumen area was found
to be 164,624 ± 22,006 µm2 in the control group, 80,654
± 17,650 µm2 in the SAH group, and 125,808 ± 23,916
µm2 in the SAH+BZV group (Table, Figure 2B). The SAH
group showed statistically significant decreased luminal

Figure 1. Basilar artery diameter measurements according to in vivo MR angiography
compared between groups. There were significant differences between the SAH group
and the control group, and also the SAH+BVZ group and the control group (*p ˂ 0.05,
***p < 0.001). Data is presented as mean ± SE.
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Table. The results of measurements.
Control

SAH

SAH+BVZ

p-value

BA diameter on MRA, (mm) [mean ± SE]

0.104 ± 0.003

0.071 ± 0.048

0.089 ± 0.003

<0.0001‡

Wall thickness (μm), [mean ± SE]

16.69 ± 1.55

31.83 ± 2.75

21.51 ± 1.39

<0.001†

Luminal area measurement (μm ), [mean ± SE]

164624 ± 22006

80654 ± 17650

125808 ± 23916

<0.05†

Apoptotic cell percentage (%), [mean ± SE]

2.67 ± 0.49

83.17 ± 1.96

68.7 ± 2.20

<0.0001‡

2

BA, basilar artery; BVZ, bevacuzimab; MRA, magnetic resonance angiography; SAH, subarachnoid hemorrhage; SE, standard
error. Statistical differences between the groups were compared by ANOVA or the Kruskal–Wallis test according to normality
test results († one-way ANOVA test, ‡ the Kruskal–Wallis test).

Figure 2. Basilar artery representative images, lumen area and wall thickness results 72 h after subarachnoid hemorrhage. A) HE staining
light microscopic images show basilar artery cross sections on the surface of pons; a) Control group, b) SAH group, c) SAH+BVZ group.
Scale bar 100 μm. B) Basilar artery lumen areas were compared between groups. There were significant differences at the SAH group
compared to the control and SAH+BVZ groups (*p < 0.05). C) Basilar artery wall thicknesses were compared between groups. There
were significant differences between the SAH group and the control group, and also the SAH+BVZ group and the control group (**p ˂
0.01, ***p < 0.001). Measurements are expressed as mean ± SE.

area compared to the control group (p < 0.05, Figure
2B). There was even a trend of increase in the luminal
area of SAH+BVZ group compared to the SAH group,
the difference was not statistically significant (p > 0.05).
Supporting this trend, there was no statistically meaningful
difference between the luminal areas of the SAH+BVZ and
the control group (p > 0.05).
There was a statistically meaningful difference between
wall thicknesses of the groups (p < 0.001, ANOVA). The
mean vessel wall thickness was found to be 16.69 ± 1.55 µm
in the control group, 31.83 ± 2.75 µm in the SAH group,
and 21.51 ± 1.39 µm in the SAH+BZV group (Table 1).

The SAH group showed statistically significant decrease in
vessel wall thickness compared to the control group (p <
0.001). The wall thickness was increased in the SAH+BVZ
group compared to the SAH group (p < 0.01, Figure 2C,
Table 1).
3.4. Analysis of intergroup apoptosis measurement
difference
The apoptotic cell death in cerebral vessels was determined
by TUNEL staining, and the TUNEL (+) endothelium was
localized on the inner surface of the corrugated internal
elastic membrane (Figure 3A). The means of the apoptotic
cell percentage were different from each other in three
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Figure 3. Basilar artery TUNEL staining results 72 h after subarachnoid hemorrhage (SAH). A) The figure shows representative
TUNEL staining images for basilar arteries at 72 h after subarachnoid hemorrhage. TUNEL positive apoptotic endothelial cell nucleus
(stained with diaminobenzidine [DAB] brown color). Normal endothelial cell nucleus (stained with methyl green); a) Control group,
b) SAH group, c) SAH+BVZ group. B) TUNEL positive cell staining results were compared between groups. There were significant
differences between the SAH group and the control group, and also the SAH+BVZ group and the control group (**p < 0.01, ***p <
0.001). Measurements are expressed as mean ± SE.

groups (p < 0.0001, the Kruskal–Wallis test). The apoptotic
cell percentage was found to be 1.83 ± 0.05 in the control
group, 83.16 ± 1.25 in the SAH group, and 62.50 ± 3.80
in the SAH+BZV group (Table 1). In the control group,
the mean of the apoptotic cell percentage was significantly
lower compared to the SAH group (p < 0.001). The means
of the apoptotic cell percentage was significantly lower in
the SAH+BZV group compared to the SAH group (p <
0.01) (Figure 3B).
4. Discussion
In this study, we demonstrated that rabbits that were
treated with BVZ after SAH had significantly less
vasospasm compared to those that were not treated with
BVZ. Additionally, we have also shown that the VEGF
pathway might be implicated in the development of
cerebral vasospasm with apoptosis pathway on cerebral
arteries after SAH.
VEGF were reported to increase in an acute phase
of aneurysmal SAH and suggested to cause cerebral
vasospasm and proliferative angiopathy in experimental
SAH [4–6]. VEGF receptor2 (VEGFR-2), which is a
major receptor of VEGF, was reported to be activated after
experimental SAH, and VEGFR2 blockage suppresses
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post-SAH blood-brain barrier (BBB) damage [12].
VEGFR involvement in the pathophysiology of SAH in
cerebral arteries was also reported [13]. To the best of
our knowledge, there is no previous study evaluating the
impact of anti-VEGF treatment effects after SAH.
VEGF has a significant role in vascular permeability
and angiogenesis during embryonic vasculogenesis
and in physiological and pathological angiogenesis in
nonneural vessels. The effects are mediated by VEGFR-2,
which is present on endothelial cells [9]. It has also
been demonstrated that VEGF enables enhanced BBB
permeability in the normal mice brain and inflammatory
disease of the mice brain [9]. The cerebral ischemia in
animals is usually studied on the model of middle cerebral
artery occlusion. These studies revealed an increase of
VEGF expression in ischemic areas of the brain [3].
Hypoxia strongly induces VEGF expression in vivo and
in vitro models. Animal studies revealed an increase
of VEGF expression as early as 3 h after induction of
hypoxia, with peak intensity after 48 h [3]. Lei et al. [12]
demonstrated that experimental SAH upregulated VEGF
expression in the cerebral cortex, causing BBB disruption.
Anti-VEGF treatment was found to be protective against
post-SAH early brain injury [12]. However, no studies
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have investigated the effects of direct blockage of VEGF on
cerebral arteries after SAH.
Bevacizumab is an agent used for cancer treatment
as a VEGF antagonist. It is a VEGF angiogenesis
inhibitor, produced by recombinant DNA technology,
and a monoclonal antibody against human VEGF-A. Its
molecular weight is 149 kDa. Instead of directly targeting
tumor cells, it targets vessels which carry oxygen and
nutrition to tumor cells [7]. BVZ binds to VEGF and
prevents the interaction of VEGF and its endothelial
surface receptor. Thus, BVZ inhibits angiogenesis by
clearing circulating VEGF effect [14].
Despite initial concerns of life-threatening hemorrhages
with anti-VEGF use in patients with brain tumors, a
review of 10,598 cancer patients in 57 clinical trials of
anti-VEGF therapy, including bevacizumab, showed that
the rate of intracranial hemorrhage, even in patients with
high-grade glioma and brain metastases, was negligible
(<1%) [15]. Additionally, a subsequent review at Memorial
Sloan Kettering Cancer Center showed an IPH frequency
of 3.7% in cancer patients receiving bevacizumab, which
was identical to a 3.6% frequency detected in comparable
patients not treated with bevacizumab [16]. A more
recent study by the German Glioma Network similarly
demonstrated no significant difference in the rate of
intracranial hemorrhages with and without BVZ therapy
(p = 0.571) [17]. Another study suggested that intracranial
hemorrhage in high-grade glioma was due to tumor
progression, rather than anti-VEGF therapy [18]. On top
of all these reports, Lin X et al. [19] reported preliminary
evidence that even rechallenging with bevacizumab
therapy may be safe. All of these studies support the view
that the intracerebral hemorrhage was unlikely to be due
to bevacizumab therapy.
There is also another concern for angiogenic blockage
increasing the risk of vasospasm [9,10,20]. Anti-VEGF
therapies in general are thought to lead to vasospasm
in tissues throughout the body via dysregulation of the
renin–angiotensin–aldosterone system [21]. VEGF has
been shown to stimulate the production of nitric oxide
by endothelial cells in arteries and arterioles, resulting in
vasodilation [10]. The reduction of the VEGF activity may
potentially increase the risk of vasospasm. Indeed, retinal
arterial vasoconstriction and systemic hypertension have
been identified as complications of anti-VEGF therapy
[11]. However, there was a unique case of a reported
glioblastoma multiforme patient who demonstrated no
clear evidence of vasospasm after SAH in the setting
of BVZ treatment. In that case, a delay of 40 days postSAH was well tolerated without clinical or radiographic
sequelae, including vasospasm or further hemorrhage [22].
Our results show the safety of BVZ in an in vivo model of
SAH. Additionally, BVZ had a vasodilatory effect on the

basilar artery which was confirmed by histopathological
and in vivo MRA results.
In our in vivo experiment, the generally accepted SAH
model was chosen for this research. Administration of
anti-VEGF antibodies reduced the vasospasm on basilar
arteries. Pathological staining results also confirmed the
antiapoptotic effect of BVZ on basilar arteries of SAHinduced rabbits. Apoptosis is one of the major cell death
patterns in ischemic penumbra (ischemic but still viable
cerebral tissue) and SAH, particularly induced by the
endoplasmic reticulum stress pathway. In our findings,
apoptosis of basilar artery sections were identified by
TUNEL staining, showing a significantly reduced number
of TUNEL-positive cells in the BVZ treatment group than
in the SAH model group. These results indicated that the
positive effects of anti-VEGF may be partially related to
their antiapoptotic effects at any rate. For this series of
phenomena, we believe that BVZ neutralizes the high
level of endogenous VEGF, which has a vasospastic and
apoptotic role at the time of SAH.
In conclusion, our study demonstrated that the
application of BVZ has a vasospasm-attenuating effect.
Inhibiting endogenous VEGF expression may decrease
cerebral vessel damage in vivo via suppressing apoptosis.
Vasospasm-reducing effect of VEGF antagonism may
be highly valuable for the literature due to concerns of
risks relating to the vasospastic effect after anti-VEGF
treatment.
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